权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder

用于筛选酒精使用障碍药物的新型人体实验室模型

基本信息

批准号：
10387543
负责人：
LARA A. RAY
金额：
$ 4.68万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-10 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10387543
关键词：
Administrative Supplement Advisory Committees Alcohol consumption Alcohols Area COVID-19 COVID-19 pandemic Clinical Clinical Research Clinical Trials Cross-Over Studies Crossover Design Cues DSM-V Detection Development Disease Double-Blind Method FDA approved Human Individual Laboratories Laboratory Study Literature Medication Management Methods Modeling Naltrexone Outcome Participant Persons Pharmaceutical Preparations Pharmacotherapy Phase Placebos Procedures Process Protocols documentation Randomized Reading Recovery Reporting Research Priority Resources Safety Self Administration Signal Transduction Telephone Testing Time Translations Treatment Efficacy United States Woman alcohol craving alcohol cue alcohol response alcohol screening alcohol use disorder base breath alcohol measurement clinically relevant cost cue reactivity drinking drinking behavior improved intrinsic motivation medication compliance men novel novel strategies pandemic disease phase 2 study phase 2 testing primary outcome recruit response screening smoking cessation

项目摘要

ABSTRACT This administrative supplement application is intended to support the timely and full completion of the proposed study and to offset delays caused by the COVID-19 Pandemic. As detailed in the application, we have dealt with a host of COVID-19 related delays, while also maintaining the laboratory open and conducting ongoing recruitment to the maximum degree allowed by the UCLA COVID-19 Response and Recovery Task Force. In this administrative supplement, we carefully justify the request for additional resources to effectively complete the original project and mitigate COVID-19 delays in recruitment. Despite the challenges of the COVID-19 pandemic our team has been resilient and hard-working. We have maintained recruitment efforts to the best of our ability and completed 19 randomizations during a full year of COVID-19 disruption. Further, we have kept the protocol integrity and have conducted daily telephone and zoom-based sessions, which enable close contact between participants and study staff. This allowed us to stay consistent with regard to the proposed protocol, provide careful medication management, verify medication compliance, and obtain all necessary clinical safety labs at the beginning of study participation. This administrative supplement will provide much-needed support a high-fidelity protocol that has been kept intact and operational despite substantial challenges associated with the pandemic.

摘要